Cytotoxicity testing of carrier-based microcomposites for DPI application

R. Ambrus, A. Pomázi, K. Réti-Nagy, F. Fenyvesi, M. Vecsernyés, Piroska Szabó-Révész

Research output: Article

7 Citations (Scopus)

Abstract

Inhalation is an attractive delivery route for systemic and local therapy. High local drug concentrations may permit non-invasive delivery, lower therapeutic doses, reduced systemic side-effects, and reduced metabolic degradation of the drug in the liver. In our earlier study, carrier-based microcomposites were prepared and investigated. The present study introduces studies of the cytotoxicity of meloxicam-containing microcomposites on monolayers of Calu-3 cells, in order to acquire information on its availability in pulmonary formulations. By relating cytotoxicity and drug dissolution, the appropriate amount of meloxicam for dry powder inhalation could be determined.

Original languageEnglish
Pages (from-to)549-550
Number of pages2
JournalPharmazie
Volume66
Issue number7
DOIs
Publication statusPublished - júl. 2011

Fingerprint

meloxicam
Inhalation
Pharmaceutical Preparations
Powders
Lung
Liver
Therapeutics

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Cytotoxicity testing of carrier-based microcomposites for DPI application. / Ambrus, R.; Pomázi, A.; Réti-Nagy, K.; Fenyvesi, F.; Vecsernyés, M.; Szabó-Révész, Piroska.

In: Pharmazie, Vol. 66, No. 7, 07.2011, p. 549-550.

Research output: Article

Ambrus, R. ; Pomázi, A. ; Réti-Nagy, K. ; Fenyvesi, F. ; Vecsernyés, M. ; Szabó-Révész, Piroska. / Cytotoxicity testing of carrier-based microcomposites for DPI application. In: Pharmazie. 2011 ; Vol. 66, No. 7. pp. 549-550.
@article{1f9ee7c717994226adc26937ece456c0,
title = "Cytotoxicity testing of carrier-based microcomposites for DPI application",
abstract = "Inhalation is an attractive delivery route for systemic and local therapy. High local drug concentrations may permit non-invasive delivery, lower therapeutic doses, reduced systemic side-effects, and reduced metabolic degradation of the drug in the liver. In our earlier study, carrier-based microcomposites were prepared and investigated. The present study introduces studies of the cytotoxicity of meloxicam-containing microcomposites on monolayers of Calu-3 cells, in order to acquire information on its availability in pulmonary formulations. By relating cytotoxicity and drug dissolution, the appropriate amount of meloxicam for dry powder inhalation could be determined.",
author = "R. Ambrus and A. Pom{\'a}zi and K. R{\'e}ti-Nagy and F. Fenyvesi and M. Vecserny{\'e}s and Piroska Szab{\'o}-R{\'e}v{\'e}sz",
year = "2011",
month = "7",
doi = "10.1691/ph.2011.0378",
language = "English",
volume = "66",
pages = "549--550",
journal = "Die Pharmazie",
issn = "0031-7144",
publisher = "Govi-Verlag Pharmazeutischer Verlag GmbH",
number = "7",

}

TY - JOUR

T1 - Cytotoxicity testing of carrier-based microcomposites for DPI application

AU - Ambrus, R.

AU - Pomázi, A.

AU - Réti-Nagy, K.

AU - Fenyvesi, F.

AU - Vecsernyés, M.

AU - Szabó-Révész, Piroska

PY - 2011/7

Y1 - 2011/7

N2 - Inhalation is an attractive delivery route for systemic and local therapy. High local drug concentrations may permit non-invasive delivery, lower therapeutic doses, reduced systemic side-effects, and reduced metabolic degradation of the drug in the liver. In our earlier study, carrier-based microcomposites were prepared and investigated. The present study introduces studies of the cytotoxicity of meloxicam-containing microcomposites on monolayers of Calu-3 cells, in order to acquire information on its availability in pulmonary formulations. By relating cytotoxicity and drug dissolution, the appropriate amount of meloxicam for dry powder inhalation could be determined.

AB - Inhalation is an attractive delivery route for systemic and local therapy. High local drug concentrations may permit non-invasive delivery, lower therapeutic doses, reduced systemic side-effects, and reduced metabolic degradation of the drug in the liver. In our earlier study, carrier-based microcomposites were prepared and investigated. The present study introduces studies of the cytotoxicity of meloxicam-containing microcomposites on monolayers of Calu-3 cells, in order to acquire information on its availability in pulmonary formulations. By relating cytotoxicity and drug dissolution, the appropriate amount of meloxicam for dry powder inhalation could be determined.

UR - http://www.scopus.com/inward/record.url?scp=79960036473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960036473&partnerID=8YFLogxK

U2 - 10.1691/ph.2011.0378

DO - 10.1691/ph.2011.0378

M3 - Article

C2 - 21812334

AN - SCOPUS:79960036473

VL - 66

SP - 549

EP - 550

JO - Die Pharmazie

JF - Die Pharmazie

SN - 0031-7144

IS - 7

ER -